Skip NavigationSkip to Content

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers

  1. Author:
    Coggins, Si'Ana A
    Laing, Eric D
    Olsen, Cara H [ORCID]
    Goguet, Emilie
    Moser, Matthew
    Jackson-Thompson, Belinda M
    Samuels, Emily C
    Pollett, Simon D
    Tribble, David R [ORCID]
    Davies, Julian
    Illinik, Luca
    Hollis-Perry, Monique
    Maiolatesi, Santina E
    Duplessis, Christopher A
    Ramsey, Kathleen F
    Reyes, Anatalio E
    Alcorta, Yolanda
    Wong, Mimi A
    Wang, Gregory
    Ortega, Orlando
    Parmelee, Edward
    Lindrose, Alyssa R [ORCID]
    Snow, Andrew L
    Malloy, Allison M W
    Letizia, Andrew G
    Ewing, Daniel
    Powers,John
    Schully, Kevin L
    Burgess, Timothy H
    Broder, Christopher C
    Mitre, Edward [ORCID]
  2. Author Address

    Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA., Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, Maryland, USA., Clinical Trials Center, Naval Medical Research Center, Silver Spring, Maryland, USA., General Dynamics Information Technology, Falls Church, Virginia, USA., Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Infectious Disease Directorate, Naval Medical Research Center, Silver Spring, Maryland, USA., Clinical Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Frederick, Maryland, USA.,
    1. Year: 2021
    2. Date: Nov 20
  1. Journal: Open Forum Infectious Diseases
    1. 9
    2. 1
    3. Pages: ofab575
  2. Type of Article: Article
  3. Article Number: ofab575
  4. ISSN: 2328-8957
  1. Abstract:

    The relationship between postvaccination symptoms and strength of antibody responses is unclear. The goal of this study was to determine whether adverse effects caused by vaccination with the Pfizer/BioNTech BNT162b2 vaccine are associated with the magnitude of vaccine-induced antibody levels. We conducted a single-center, observational cohort study consisting of generally healthy adult participants that were not severely immunocompromised, had no history of coronavirus disease 2019, and were seronegative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein before vaccination. Severity of vaccine-associated symptoms was obtained through participant-completed questionnaires. Testing for immunoglobulin G antibodies against SARS-CoV-2 spike protein and receptor-binding domain was conducted using microsphere-based multiplex immunoassays performed on serum samples collected at monthly visits. Neutralizing antibody titers were determined by microneutralization assays. Two hundred six participants were evaluated (69.4% female, median age 41.5 years old). We found no correlation between vaccine-associated symptom severity scores and vaccine-induced antibody titers 1 month after vaccination. We also observed that (1) postvaccination symptoms were inversely correlated with age and weight and more common in women, (2) systemic symptoms were more frequent after the second vaccination, (3) high symptom scores after first vaccination were predictive of high symptom scores after second vaccination, and (4) older age was associated with lower titers. Lack of postvaccination symptoms after receipt of the BNT162b2 vaccine does not equate to lack of vaccine-induced antibodies 1 month after vaccination. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2021.

    See More

External Sources

  1. DOI: 10.1093/ofid/ofab575
  2. PMID: 35047649
  3. PMCID: PMC8759445
  4. WOS: 000744981900010
  5. PII : ofab575

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel